Camrelizumab plus chemotherapy as induction therapy followed by concurrent chemoradiotherapy and camrelizumab consolidation in limited-stage small cell lung cancer: a randomized phase II trial
Definitive chemoradiotherapy followed by immunotherapy consolidation is the current standard of care for limited-stage small cell lung cancer (LS-SCLC). We conducted a randomized phase II trial (ChiCTR2000032275) to evaluate a camrelizumab-based induction–consolidation strategy in previously untreated patients with LS-...